ROLZAVOSORITIDE
UNII 8Y5K6WLC4Y

Substance Identification & Data

This profile provides standardized clinical and technical data for Rolzavosoritide, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 8Y5K6WLC4Y.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3067191-26-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

8Y5K6WLC4Y

CAS Registry Number

3067191-26-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

ROLZAVOSORITIDE

Official standardized name for this substance within the FDA UNII nomenclature system.

INN ID

13989

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Rolzavosoritide. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

ROLZAVOSORITIDE

Common Names & Synonyms

C-TYPE NATRIURETIC PEPTIDE (CNP, CNP2, NPPC), L-PROLYLGLYCYL(C-TERMINAL 37-PEPTIDE (CNP-37)) (1-39 IN THE REAL SEQUENCE), SUBSTITUTED AT N6 OF THE L-LYSYL RESIDUE 27 WITH A (28S)-28,46-DICARBOXY-3-(2-HYDROXYETHYL)-7,16,25,30-TETRAOXO-9,12,18,21-TETRAOXA-3,6,15,24,29-PENTAAZAHEXATETRACONTAN-1-OYL GROUP; S23,S39 -CYCLO(L-PROLYLGLYCYL-L-GLUTAMINYL-L-.ALPHA.-GLUTAMYL-L-HISTIDYL-L-PROLYL-L -ASPARAGINYL-L-ALANYL-L-ARGINYL-L-LYSYL-L-TYROSYL-L-LYSYLGLYCYL- L-ALANYL-L-ASPARAGINYL-L-LYSYL-L-LYSYLGLYCYL-L-LEUCYL-L-SERYL-L-LYSYLGLYCYL-L-CYSTEINYL-L-PHENYLALANYLGLYCYL-L-LEUCYL-N6-((28S)-28,46-DICARBOXY-3-(2-HYDROXYETHYL)-7,16,25,30-TETRAOXO-9,12,18,21-TETRAOXA-3,6,15,24,29-PENTAAZAHEXATETRACONTAN-1-OYL)-L-LYSYL-L-LEUCYL-L-.ALPHA.-ASPARTYL-L-ARGINYL-L-ISOLEUCYLGLYCYL-L-SERYL-L-METHIONYL-L-SERYLGLYCYL-L-LEUCYLGLYCYL-L-CYSTEINE)

L-CYSTEINE, L-PROLYLGLYCYL-L-GLUTAMINYL-L-.ALPHA.-GLUTAMYL-L-HISTIDYL-L-PROLYL-L-ASPARAGINYL-L-ALANYL-L-ARGINYL-L-LYSYL-L-TYROSYL-L-LYSYLGLYCYL-L-ALANYL-L-ASPARAGINYL-L-LYSYL-L-LYSYLGLYCYL-L-LEUCYL-L-SERYL-L-LYSYLGLYCYL-L-CYSTEINYL-L-PHENYLALANYLGLYCYL-L-LEUCYL-N6-(N-(17-CARBOXY-1-OXOHEPTADECYL)-L-.GAMMA.-GLUTAMYL-2-(2-(2-AMINOETHOXY)ETHOXY)ACETYL-2-(2-(2-AMINOETHOXY)ETHOXY)ACETYL-2-((2-AMINOETHYL)(2-HYDROXYETHYL)AMINO)ACETYL)-L-LYSYL-L-LEUCYL-L-.ALPHA.-ASPARTYL-L-ARGINYL-L-ISOLEUCYLGLYCYL-L-SERYL-L-METHIONYL-L-SERYLGLYCYL-L-LEUCYLGLYCYL-, CYCLIC (23->39)-DISULFIDE

ROLZAVOSORITIDE [INN]

External Clinical & Regulatory Resources

Previous UNII8Y5JDG542Y

Next UNII8Y5Y4EEO2V